Merck reported a better-than-expected quarterly profit and raised its full-year earnings forecast as sales of its blockbuster immunotherapy, Keytruda, crossed the $3 billion mark for the first time in a single quarter.
from Earnings https://ift.tt/2MSGKEe
via IFTTT
No comments:
Post a Comment